Cancer Clinical Trial
Official title:
Age-Related Eye Disease Study 2 (AREDS2) 10-Year Follow-On Study
Background:
Age-related macular degeneration (AMD) and cataracts are two eye diseases. They were studied
in the Age-Related Eye Disease Study (AREDS2) and the AREDS2 Follow-On study. These studies
followed the natural course of the diseases. They also provided data on the long-term effects
of certain oral supplements on AMD.
Objective:
To study the long-term effects of oral supplements on several things. These include
incidences of lung cancer, development of late AMD, cataract surgery, cognitive function, and
cardiovascular events.
Eligibility:
Former AREDS2 and AREDS2 Follow-On participants
Design:
Participants will have 1 visit. It will include:
An eye exam that tests how well participants can see, measures eye pressure, and checks eye
movements. The pupil will be dilated with eye drops. Pictures will be taken of the retina and
the inside of the eye.
Participants will grip a device in their hand to measure their grip strength.
A blood sample will be taken. This will be stored for future genetic research. Cells may be
created from the sample.
A small sample of skin will be taken.
Sponsoring Institution: National Eye Institute
Objective: The overall objective of this extended follow-up study is to provide data
regarding the incidence of late age-related macular degeneration (AMD), cataract surgery and
lung cancer in the approximately 1,200 AREDS2 study participants enrolled in the Follow-on
study. The specific objectives for the study are to:
- Study the rates of progression to late AMD, neovascular AMD, or geographic atrophy
associated with AMD.
- To seek incidences of lung cancer, by treatment assignment.
- To assess cognitive understanding by phone prior to coming into the clinic.
- To seek incidences of cardiovascular events.
Study Population: Up to 3,200 participants who were previously enrolled in the AREDS2 and
AREDS2 Follow-on protocols are currently followed by telephone contact every six months for
the past four years. It is expected that 1,200 of these 3,200 participants will be eligible
to participate in the study. Up to 83 participants will be enrolled at the NEI.
Design: This is an extension of the multicenter, randomized trial of lutein, zeaxanthin and
omega-3 polyunsaturated fatty acids in the AMD AREDS2 trial. Data for this extension will be
collected by staff at selected AREDS2 clinical sites via an in-clinic visit.
Outcome Measures: The primary outcomes of the study will be the rates of progression to late
AMD, neovascular AMD or geographic atrophy associated with AMD. Also of interest are the
long-term rates of progression to late AMD, incidents of lung cancer and cataract surgery.
Participant reports of incident cardiovascular events will be collected as secondary
outcomes.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|